Breast cancer remains one of the most prevalent malignancies among women worldwide, where the expression level of human epidermal growth factor receptor 2 (HER2) plays a pivotal role in both therapeutic decision-making and prognostic stratification. This evidence concerns the gene ERBB2 and breast carcinoma.